BIOVF News and Press, Swedish Orphan Biovit Ord From 02/20/19

Swedish Orphan Biovitrum AB ( OTCPK:BIOVF ): Q4 GAAP EPS of SEK2.20. More news on: Swedish Orphan Biovitrum AB, Earnings news and commentary, Healthcare stocks news, Read more ...

STOCKHOLM , Feb. 7, 2019 /PRNewswire/ -- Sobi™ will present data at the European Association of Haemophilia and Allied Disorders (EAHAD) conference in Prague, Czech Republic , 6-8 February 2019 , showing evidence on the safety, efficacy and long-term benefits of its extended ha...

The FDA designates AstraZeneca's (NYSE: AZN ) MEDI8897, an extended half-life respiratory syncytial virus (RSV) F monoclonal antibody, a Breakthrough Therapy for the prevention of lower respiratory tract infection caused by RSV. More news on: AstraZeneca Group plc, Sanofi, Swedish Orphan...

I have been writing a lot about - mostly European - holding companies lately. For those interested in this articles, they can be found here and here . There have been comments which made me aware of yet another such company: Swedish Investor AB ( IVXSF , IVSBF ). Please note that whereve...

The following slide deck was published by Swedish Orphan Biovitrum AB in conjunction with this Read more ...

Swedish Orphan Biovitrum AB (BIOVF) Merger & Acquisition Conference Call November 13, 2018 8:00 AM ET Executives Guido Oelkers – Chief Executive Officer Henrik Stenqvist – Chief Financial Officer Milan Zdravkovic – Head-R&D Analysts Peter Sehest...

Swedish Orphan Biovitrum AB ( OTCPK:BIOVF ) (Sobi) has agreed to acquire the U.S. rights to AstraZeneca's (NYSE: AZN ) RSV med Synagis (palivizumab) and 50% of the future U.S. earnings of candidate MEDI8897 for $1.0B in cash and and $500M in newly issued Sobi stock. More news on: Swedish...

STOCKHOLM , Nov. 13, 2018 /PRNewswire/ --  Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) has entered into agreements to acquire the perpetual rights to Synagis® (palivizumab) in the US from AstraZeneca and to participate in 50 per cent of the future earnings of t...

Swedish Orphan Biovitrum AB (BIOVF) Q3 2018 Earnings Conference Call October 31, 2018 08:00 ET Executives Guido Oelkers - President & CEO Henrik Stenqvist - CFO Armin Reininger - Head, Medical & Scientific Affairs Analysts Kyung Yang - Jefferies Peter Sehested - H...

The following slide deck was published by Swedish Orphan Biovitrum AB in conjunction with their 2018 Q3 earnings Read more ...